Immunoassay for breast cancer employing monoclonal antibodies

• US 4,707,438 A
• Filed: 02/15/1985
• Issued: 11/17/1987
• Est. Priority Date: 08/22/1984
• Status: Expired due to Fees

• Current Assignee: Tel Aviv University, Teva Pharmaceutical Industries Limited
• Original Assignee: Tel Aviv University, Teva Pharmaceutical Industries Limited
• Inventors: Keydar, Iafa
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US06/702,055
• Time in Patent Office: 1,005 Days
• Field of Search: 436/548, 436/513, 436/804, 436/546, 436/540, 436/529, 436/503, 436/813, 435/68, 435/172.2, 435/240, 435/241, 435/948, 435/43, 435/7, 435/5, 435/21, 435/28, 424/85, 424/86, 424/87, 260/112 R, 935/89, 935/103, 935/106, 935/108, 935/110, 530/387, 530/808
• US Class Current: 435/5
• CPC Class Codes: C07K 16/10 from RNA viruses
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: G01N 2474/20 Immunohistochemistry assay
• CPC Class Codes: Y10S 435/948 using viruses or cell lines
• CPC Class Codes: Y10S 435/971 Capture of complex after antigen-antibody reaction
• CPC Class Codes: Y10S 436/804 Radioisotope, e.g. radioimmunoassay
• CPC Class Codes: Y10S 436/813 Cancer
• CPC Class Codes: Y10S 530/808 Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Abstract

An immunoassay for diagnosing and monitoring human breast cancer. The assay employs a monoclonal antibody which recognizes a human mammary tumor virus derived from the T47D clone-10 breast cancer cell line (HMTV). The monoclonal antibody is produced by the hybridoma cell line deposited with the American Type Culture Collection under ATCC Accession No. HB 8630.

When the immunoassay is performed on a tissue sample from a subject, the sample is contacted with monoclonal antibody ATCC Accession No. HB 8630 so as to form an antibody-antigen complex between the monoclonal antibody and any HMTV antigens which may be present in the sample. This antibody-antigen complex is then detected employing a second detectable antibody specific to the first monoclonal antibody. The presence or absence of the complex indicates the presence or absence of breast cancer in the subject.

When the immunoassay is performed on a body fluid sample from a subject, the sample is first contacted with a detectable soluble antibody so as to form an antibody-antigen complex between the antibody and any HMTV antigens which may be present in the sample. The fluid sample is then contacted by a second antibody which is attached to a solid support. Either the first or second antibody is the monoclonal antibody produced by hybridoma cell line ATCC Accession No. HB 8630. The presence or absence of the complex indicates the presence or absence of human breast cancer in the subject.

Claims

1. The hybridoma cell line having ATCC Accession No. HB 8630 which results from the fusion of

spleen cells of Balb/c mice immunized with human mammary tumor virus particles derived from T47D clone-10, and

NS-1 non-producing immunoglobin myelomas derived from Balb/c mice.

2. The monoclonal antibody which recognizes human mammary tumor virus-like particles derived from T47D clone-10 breast cancer cell line and which is produced and secreted by the hybridoma cell line of claim 1 wherein said monoclonal antibody is characterized by a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin.

3. An immunoassay for diagnosing and monitoring human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin, comprising:

contacting a sample with first and second antibodies to form an antibody-antigen complex with any human mammary tumor virus contained in said sample, one of said first and second antibodies being detectable and the other being the monoclonal antibody produced and secreted by hybridoma cell line ATCC Accession determining the presence or absence of detectable antibody in said antibody-antigen complex.

4. An immunoassay according to claim 3, wherein said detectable antibody is linked to an enzyme which catalyzes a detectable reaction.

5. An immunoassay according to claim 4, wherein said enzyme is alkaline phosphatase or horseradish peroxidase.

6. An immunoassay according to claim 3, wherein said detectable antibody is radioactively labeled.

7. An immunoassay according to claim 6, wherein said antibody is labeled with ¹²⁵ I.

8. An immunoassay according to claim 3, wherein said sample is a tissue sample and wherein said first antibody is said monoclonal antibody and said second antibody is detectable and directed to said monoclonal antibody.

9. An immunoassay according to claim 8, wherein said tissue sample is breast tissue.

20. An immunoassay according to claim 9, wherein said first antibody is said monoclonal antibody and said second antibody is affinity purified rabbit antisera against human mammary tumor virus produced by the T47D clone-10 cell line.

10. An immunoassay for diagnosing and monitoring human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin, comprising:

contacting a tissue sample with monoclonal antibody derived from hybridoma cell line ATCC Accession No. HB 8630 to form an antibody-antigen complex between the monoclonal antibody and any human mammary tumor virus contained in said tissue sample;

thereafter contacting said tissue sample with a detectable antibody directed to said monoclonal antibody; and

determining the presence or absence of detectable antibody in said complex.

11. An immunoassay according to claim 10, further comprising the step of separating said tissue sample from unreacted antibody prior to detecting said tissue sample with said detectable antibody.

12. An immunoassay according to claim 11, wherein said detectable antibody is radioactively labeled.

13. An immunoassay according to claim 12, wherein said antibody is labeled with ¹²⁵ I.

14. An immunoassay according to claim 11, wherein said detectable antibody is an antibody linked to an enzyme which catalyzes a detectable reaction.

15. An immunoassay according to claim 14, wherein said enzyme is alkaline phosphatase or horseradish peroxidase.

16. An immunoassay according to claim 14, wherein said detectable antibody is rabbit anti-mouse immunoglobin linked to an enzyme which catalyzes a detectable reaction.

17. An immunoassay according to claim 16, wherein said detectable antibody is a conjugate of horseradish peroxidase and rabbit anti-mouse immunoglobin or a conjugate of alkaline phosphatase and rabbit anti-mouse immunoglobin.

18. An immunoassay for diagnosing and monitoring human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin, comprising:

contacting a fluid sample with a first soluble antibody to form an antibody-antigen complex with any human mammary tumor virus contained in said sample, said first antibody being detectable;

contacting said complex with a second antibody to said human mammary tumor virus, said second antibody being attached to a solid matrix, and one of said first or second antibodies being the monoclonal antibody produced and secreted by hybridoma cell line ATCC Accession No. HB 8630; and

detecting or measuring the presence or absence of detectable antibody in said complex.

19. An immunoassay according to claim 18, wherein said solid matrix is separated from said fluid sample and said first antibody prior to said detecting or measuring step.

21. An immunoassay according to claim 19, wherein said first and second antibodies are monoclonal antibodies.

22. In an immunoassay for diagnosing human breast cancer, wherein said immunoassay is characterized by the use of monoclonal antibodies having a high percent accuracy of recognition reaching up to 90% to 100% of all breast metastases, without significant undesirable false positives or cross reactions with malignancies of non-breast origin, comprising contacting a sample with first and second antibodies to form an antibody-antigen complex with any human mammary tumor virus contained in said sample, wherein one of said antibodies is labeled and at least one of said antibodies is a monoclonal antibody which recognizes said human mammary tumor virus and determining the presence or absence of detectable antibody in said complex, the improvement comprising using as said monoclonal antibody the monoclonal antibody produced and secreted by hybridoma cell line having ATCC Accession No. HB 8630.